Supplement basal media with ITSE + A to a final 1x-2x concentration. Reduce typical percentage of added FBS by 50-90%. Expand cells as normal in ITSE + A supplemented media for desired expansion time. Perform post-expansion cell count and doubling-time calculation.
Posted By Attie Pennybaker on 3/4/19 12:30 PM
The International Society of Cell & Gene Therapy (ISCT) has a rich history of bringing together leading professionals who are committed to advancing the field. This year, from May 2nd to May 5th, nearly 1500 of those leading professionals from across the globe gathered in the bustling Canadian city of Montreal to share the latest breakthroughs and innovations, partake in thought-provoking conversations, and create lasting connections at the ISCT 2018 annual conference. Although I did not get a chance to indulge in the famed Canadian poutine dish, I left the country full of something better: new ideas, deeper knowledge, and a greater appreciation for the potential implications and benefits of cell and gene therapy innovation.
Innovation, technology, and success has driven the vaccine industry to remain at the forefront of biotechnology and this year’s World Vaccine Congress was no exception. Taking place April 2-5 in Washington D.C., the 18th annual World Vaccine Congress lured over 1000 attendees from more than 300 leading global institutions to deliver the largest establishment of this event yet. Being surrounded by such a vast amount of knowledge and key influencers, my experience representing InVitria here was one full of inspiration.